Skip to content

Correlation study of cyclopofol combined with nalbuphine in painless gastroenteroscopy

Correlation study of cyclopofol combined with nalbuphine in painless gastroenteroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067350
Enrollment
Unknown
Registered
2023-01-05
Start date
2023-01-16
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative vital signs

Interventions

Group 2:Propofol

Sponsors

The 980th Hospital of Joint Logistics Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: With painless gastroenteroscopy indication and tolerance, ASA grade I-II, age 18-65 years old, BMI < 30 kg/m2, normal liver and kidney function.

Exclusion criteria

Exclusion criteria: Patients with history of anesthetic allergy and contraindications, patients with severe organ dysfunction such as heart, liver and kidney, long-term use of opioids, language, hearing and mental disorders, family members of patients with examination time > 30 min; or patients themselves refused.

Design outcomes

Primary

MeasureTime frame
Sedation success rate and overall incidence of adverse events;

Secondary

MeasureTime frame
Operating time;Anesthesia induction time;time of awakening;the total dosage of drugs;heart rate;Pulse oxygen saturation;blood pressure;rate of injection pain ;satisfaction of doctors and patients;

Countries

China

Contacts

Public ContactWu Yu

The 980th Hospital of Joint Logistics Support Force

vwuyuv@163.com+86 186 3348 7638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026